Bookbuilding IPO | ₹655 Cr | Listed at BSE, NSE
Corona Remedies IPO is a book build issue of ₹655.37 crores. The issue is entirely an offer for sale of 0.62 crore shares of ₹655.37 crore.
Corona Remedies IPO bidding started from Dec 8, 2025 and ended on Dec 10, 2025. The allotment for Corona Remedies IPO was finalized on Dec 11, 2025. The shares got listed on BSE, NSE on Dec 15, 2025.
Corona Remedies IPO price band is set at ₹1,062 per share. The lot size for an application is 14. The minimum amount of investment required by an retail is ₹14,868 (14 shares) (based on upper price). The lot size investment for sNII is 14 lots (196 shares), amounting to ₹2,08,152, and for bNII, it is 68 lots (952 shares), amounting to ₹10,11,024.
The issue includes a reservation of up to 58,035 shares for employees offered at a discount of ₹54.00 to the issue price.
JM Financial Ltd. is the book running lead manager and Bigshare Services Pvt.Ltd. is the registrar of the issue.
Refer to Corona Remedies IPO RHP for detailed Information.
IPO Open
Mon, Dec 8, 2025
IPO Close
Wed, Dec 10, 2025
Issue Price
₹1062 per share
Market Cap (Pre-IPO)
₹6,495.20 Cr
| IPO Date | 8 to 10 Dec, 2025 |
| Listed on | Mon, Dec 15, 2025 |
| Face Value | ₹10 per share |
| Price Band | ₹1008 to ₹1062 |
| Issue Price | ₹1062 per share |
| Lot Size | 14 Shares |
| Sale Type | Offer For Sale |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Employee Discount | ₹54.00 |
| Total Issue Size | 61,74,051 shares (agg. up to ₹655 Cr) |
| Share Holding Pre Issue | 6,11,60,088 shares |
| Share Holding Post Issue | 6,11,60,088 shares |
| BSE Script Code / NSE Symbol | 544644 / CORONA |
| ISIN | INE02ZQ01018 |
Corona Remedies IPO offers total 61,74,051 shares. Out of which 30,58,007 (49.53%) allocated to QIB, 12,23,203 (19.81%) allocated to QIB (Ex- Anchor), 9,17,403 (14.86%) allocated to NII 21,40,606 (34.67%) allocated to RII and 18,34,804 (29.72%) allocated to Anchor investors.
| Investor Category | Shares Offered | Max Allottees |
|---|---|---|
| QIB Shares Offered | 30,58,007 (49.53%) | NA |
| − Anchor Investor Shares Offered | 18,34,804 (29.72%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 12,23,203 (19.81%) | NA |
| NII (HNI) Shares Offered | 9,17,403 (14.86%) | NA |
| − bNII > ₹10L | 6,11,602 (9.91%) | 3,120 |
| − sNII < ₹10L | 3,05,801 (4.95%) | 1,560 |
| Retail Shares Offered | 21,40,606 (34.67%) | 1,52,900 |
| Employee Shares Offered | 58,035 (0.94%) | NA |
| Total Shares Offered | 61,74,051 (100.00%) |
Investors can bid for a minimum of 14 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 14 | ₹14,868 |
| Retail (Max) | 13 | 182 | ₹1,93,284 |
| S-HNI (Min) | 14 | 196 | ₹2,08,152 |
| S-HNI (Max) | 67 | 938 | ₹9,96,156 |
| B-HNI (Min) | 68 | 952 | ₹10,11,024 |
Corona Remedies IPO raises ₹194.86 crore from anchor investors. Corona Remedies IPO Anchor bid date is December 5, 2025.
📝 Anchor Investors Letter (PDF)
| Bid Date | Fri, Dec 5, 2025 |
| Shares Offered | 18,34,804 |
| Anchor Portion (₹ Cr.) | 194.86 |
| Anchor lock-in period end date for 50% shares (30 Days) | Fri, Jan 9, 2026 |
| Anchor lock-in period end date for remaining shares (90 Days) | Tue, Mar 10, 2026 |
| Application Category | Maximum Bidding Limits | Bidding at Cut-off Price Allowed |
|---|---|---|
| Only RII | Up to Rs 2 Lakhs | Yes |
| Only sNII | Rs 2 Lakhs to Rs 10 Lakhs | No |
| Only bNII | Rs 10 Lakhs to NII Reservation Portion | No |
| Only employee | Up to Rs 5 Lakhs | Yes |
| Employee + RII/NII |
|
Yes for Employee and RII/NII |
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.
As of June 30, 2025, the company's diverse portfolio includes 71 brands across therapeutic areas like women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory).
The company has a pan-India marketing and distribution network with 2,671 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas.
The company has two manufacturing facilities, located in the states of Gujarat with an aggregate installed capacity for formulations of 1,285.44 million units per annum.
Competitive Strength:
Corona Remedies Ltd.'s revenue increased by 18% and profit after tax (PAT) rose by 65% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 1,012.38 | 929.86 | 830.58 | 595.02 |
| Total Income | 348.56 | 1,202.35 | 1,020.93 | 891.10 |
| Profit After Tax | 46.20 | 149.43 | 90.50 | 84.93 |
| EBITDA | 71.80 | 245.91 | 161.19 | 135.03 |
| NET Worth | 607.02 | 606.34 | 480.41 | 408.52 |
| Reserves and Surplus | 545.86 | 545.18 | 419.25 | 347.36 |
| Total Borrowing | 106.65 | 62.70 | 134.14 | 2.33 |
| Amount in ₹ Crore | ||||
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 27.50% |
| ROCE | 41.32% |
| Debt/Equity | 0.10 |
| RoNW | 24.65% |
| PAT Margin | 12.49% |
| EBITDA Margin | 20.55% |
| Price to Book Value | 10.71 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 24.43 | 30.21 |
| P/E (x) | 43.47 | 35.15 |
| Promoter Holding | 72.50% | 69% |
| Market Cap | ₹6,495.20 Cr. |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | BRLMs fees and commissions (including underwriting commission, brokerage and selling commission) | 21.03 |
| 2 | Fees payable to the Registrar to the Offer | 0.50 |
| 3 | Selling commission/processing fee for SCSBs and Bankers to the Offer, fee payable to the Sponsor Bank(s) for Bids made by RIIs using UPI, brokerage and selling commission and bidding charges for the Members of the Syndicate, Registered Brokers, RTAs and CDPs | 3.07 |
| 4 | Advertising and marketing expenses | 2.41 |
| 5 | Others | |
| 6 | Listing fees, SEBI filing fees, upload fees, BSE and NSE processing fees, book building software fees | 7.11 |
| 7 | Other regulatory expenses | |
| 8 | Printing and stationery expenses | 1.17 |
| 9 | Fees payable to legal counsels | 8.81 |
| 10 | Fees payable to other advisors to the Offer, including but not limited to Statutory Auditors, independent chartered accountant, practising company secretary, industry expert | 4.01 |
| 11 | Miscellaneous | 3.85 |
| Price Details | BSE | NSE |
|---|---|---|
| Final Issue Price | ₹1,062.00 | ₹1,062.00 |
| Open | ₹1,452.00 | ₹1,470.00 |
| Low | ₹1,412.65 | ₹1,413.00 |
| High | ₹1,499.00 | ₹1,497.80 |
| Last Trade | ₹1,437.20 | ₹1,438.40 |
Corona Remedies IPO is a main-board IPO of 61,74,051 equity shares of the face value of ₹10 aggregating up to ₹655 Crores. The issue is priced at ₹1062 per share. The minimum order quantity is 14.
The IPO opens on Mon, Dec 8, 2025, and closes on Wed, Dec 10, 2025.
Bigshare Services Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Corona Remedies IPO using UPI as a payment gateway. Zerodha customers can apply in Corona Remedies IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Corona Remedies IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Corona Remedies IPO opens on Mon, Dec 8, 2025 and closes on Wed, Dec 10, 2025.
Corona Remedies IPO lot size is 14, and the minimum amount required for application is ₹14,868.
You can apply in Corona Remedies IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Corona Remedies IPO will be done on Thursday, December 11, 2025, and the allotted shares will be credited to your demat account by Fri, Dec 12, 2025. Check the Corona Remedies IPO allotment status.
The Corona Remedies IPO listing date is on Mon, Dec 15, 2025.
